

REGENERON PHARMACEUTICALS INC

Form 8-K

June 08, 2007

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 8, 2007**

**REGENERON PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

**New York**

**000-19034**

**133444607**

(State or other jurisdiction of  
incorporation)

(Commission File Number)

**(I.R.S. Employer  
Identification Number)**

**777 Old Saw Mill River Road, Tarrytown, New York**

**10591-6707**

**(Address of principal executive offices)**

**(Zip Code)**

**(914) 347-7000**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

On June 8, 2007, Regeneron's President and Chief Executive Officer, Dr. Leonard Schleifer, is scheduled to present a brief report on Regeneron's business at the company's Annual Meeting of Shareholders to be held at the Westchester Marriott Hotel, 670 White Plains Road, Tarrytown, New York. The overheads for this presentation are furnished as Exhibit 99(a) to this Form 8-K.

**Item 9.01 Financial Statements and Exhibits**

(c) Exhibits

99(a) Overheads for presentation at Regeneron's Annual Meeting of Shareholders to be held on June 8, 2007.

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REGENERON PHARMACEUTICALS, INC.

Dated: June 8, 2007

By: /s/ Stuart Kolinski  
Stuart Kolinski  
Vice President and General Counsel

2

---

**Exhibit Index**

<b>Number</b>	<b>Description</b>
99(a)	Overheads for presentation at Regeneron's Annual Meeting of Shareholders to be held on June 8, 2007.

3